BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37324188)

  • 1. Identification and validation of novel signature associated with hepatocellular carcinoma prognosis using Single-cell and WGCNA analysis.
    Song H; Ge Y; Xu J; Shen R; Zhang PC; Wang GQ; Liu B
    Int J Med Sci; 2023; 20(7):870-887. PubMed ID: 37324188
    [No Abstract]   [Full Text] [Related]  

  • 2. [Differential analysis of gene expression profiles in hepatocellular carcinoma patients with high and low levels of alpha-fetoprotein].
    Wang XJ; Shen RF; Wang X; Wang YR; Xiao T
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):396-402. PubMed ID: 32482029
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification and validation of the necroptosis-related gene signature related to prognosis and tumor immune in hepatocellular carcinoma.
    Xiang Z; Mranda GM; Zhou X; Xue Y; Wang Y; Wei T; Liu J; Ding Y
    Medicine (Baltimore); 2022 Sep; 101(36):e30219. PubMed ID: 36086716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Necroptosis-driving genes
    Nicolè L; Sanavia T; Cappellesso R; Maffeis V; Akiba J; Kawahara A; Naito Y; Radu CM; Simioni P; Serafin D; Cortese G; Guido M; Zanus G; Yano H; Fassina A
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and validation of a prognostic signature based on necroptosis-related genes in hepatocellular carcinoma.
    Peng YL; Wang LX; Li MY; Liu LP; Li RS
    PLoS One; 2023; 18(2):e0279744. PubMed ID: 36795724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma.
    Chen J; Wang H; Zhou L; Liu Z; Chen H; Tan X
    Cancer Med; 2022 Dec; 11(24):5079-5096. PubMed ID: 35560794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration and validation of a novel signature of seven necroptosis-related genes to improve the clinical outcome of hepatocellular carcinoma.
    Tao Q; Lang Z; Li Y; Gao Y; Lin L; Yu Z; Zheng J; Yu S
    BMC Cancer; 2023 Oct; 23(1):1029. PubMed ID: 37875823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a Necroptosis-Related miRNA Signature for Predicting the Prognosis of Patients With Hepatocellular Carcinoma.
    Meng T; Wang Q; Yang Y; Ren Y; Shi Y
    Front Genet; 2022; 13():825261. PubMed ID: 35495130
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the Prognosis Prediction Ability of a Necroptosis-Related Gene Signature and its Relationship With the Hepatocellular Carcinoma Immune Microenvironment Using Bioinformatics Analysis and Experimental Validation.
    Guan R; Mei J; Guo R
    Technol Cancer Res Treat; 2023; 22():15330338231182208. PubMed ID: 37335078
    [No Abstract]   [Full Text] [Related]  

  • 11. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SFPQ promotes the proliferation, migration and invasion of hepatocellular carcinoma cells and is associated with poor prognosis.
    Lin Y; Zhong W; Lin Q; Ye Y; Li S; Chen H; Liu H; Xu L; Zhuang W; Chen S; Lin Y; Wang Q
    Am J Cancer Res; 2023; 13(6):2269-2284. PubMed ID: 37424798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A necroptosis-related gene signature to predict prognosis and immune features in hepatocellular carcinoma.
    Zhang K; Li J; Yuan E
    BMC Cancer; 2023 Jul; 23(1):660. PubMed ID: 37452311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and analysis of necroptosis-associated signatures for prognostic and immune microenvironment evaluation in hepatocellular carcinoma.
    Lu J; Yu C; Bao Q; Zhang X; Wang J
    Front Immunol; 2022; 13():973649. PubMed ID: 36081504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification.
    Sun K; Huang C; Li JZ; Luo ZX
    World J Surg Oncol; 2022 Oct; 20(1):342. PubMed ID: 36253777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and validation of a prognostic marker and risk model for HCC ultrasound therapy combined with WGCNA identification.
    Bi Y; Jing Y; Guo L
    Front Genet; 2022; 13():1017551. PubMed ID: 36263426
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.
    Dai K; Liu C; Guan G; Cai J; Wu L
    BMC Cancer; 2022 May; 22(1):496. PubMed ID: 35513781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a mitochondrial energy metabolism-related risk model in hepatocellular carcinoma.
    Gao X; Xu M; Wang H; Xia Z; Sun H; Liu M; Zhao S; Yang F; Niu Z; Gao H; Zhu H; Lu J; Zhou X
    Gene; 2023 Mar; 855():147133. PubMed ID: 36565797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.
    Li X; Lin J; Pan Y; Cui P; Xia J
    Technol Cancer Res Treat; 2021; 20():15330338211041425. PubMed ID: 34866477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.